Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
General Internal Medicine
Would you ever omit adjuvant therapy for rectal cancer in patients who underwent primary resection (TME), without any neoadjuvant therapy?
What about T3N0 disease? Would you use a recurrence score to help inform decisions?
Related Questions
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Would you change treatment approach for rectal cancer with an associated intussusception?
Which patients do you use oral contrast in staging CT scans?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
What is your preferred way of administering nivolumab/ipilimumab in GI cancers?
Would you administer adjuvant chemotherapy for extrahepatic cholangiocarcinoma that has received neoadjuvant therapy and achieved near CR?
Do patients with central adrenal insufficiency on maintenance hydrocortisone therapy require doubling of their corticosteroid during chemotherapy cycles?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
Would you offer zolbetuximab in a non-Asian population?
If using GCSF with mFOLFIRINOX, would you ever use it during day 1? (so the injection would be during 5FU infusion)?